Jackson Square Partners LLC Decreases Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Jackson Square Partners LLC trimmed its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 16.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 134,927 shares of the medical research company’s stock after selling 26,998 shares during the quarter. Charles River Laboratories International accounts for about 2.7% of Jackson Square Partners LLC’s investment portfolio, making the stock its 11th biggest position. Jackson Square Partners LLC owned approximately 0.26% of Charles River Laboratories International worth $24,908,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Versant Capital Management Inc raised its position in shares of Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. raised its holdings in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 65 shares in the last quarter. Tortoise Investment Management LLC boosted its stake in Charles River Laboratories International by 77.7% during the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock valued at $49,000 after acquiring an additional 115 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in Charles River Laboratories International during the 3rd quarter worth $59,000. Finally, ORG Wealth Partners LLC bought a new stake in shares of Charles River Laboratories International in the 4th quarter worth about $56,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on CRL shares. The Goldman Sachs Group cut shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $190.00 to $170.00 in a research report on Friday. William Blair downgraded shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. JPMorgan Chase & Co. lowered their price objective on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a research note on Thursday, February 20th. Redburn Atlantic raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price target for the company in a research note on Monday, March 3rd. Finally, Bank of America cut their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. One analyst has rated the stock with a sell rating and sixteen have given a hold rating to the company’s stock. Based on data from MarketBeat, Charles River Laboratories International currently has a consensus rating of “Hold” and an average target price of $189.77.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, CEO James C. Foster acquired 6,075 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 20th. The stock was acquired at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the purchase, the chief executive officer now owns 183,639 shares in the company, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Birgit Girshick bought 1,514 shares of the stock in a transaction on Thursday, February 20th. The shares were acquired at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the transaction, the chief operating officer now directly owns 55,058 shares of the company’s stock, valued at approximately $9,064,198.54. The trade was a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Trading Up 0.0 %

Shares of NYSE:CRL opened at $167.29 on Tuesday. The firm has a fifty day moving average of $165.66 and a two-hundred day moving average of $183.49. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a 12-month low of $150.79 and a 12-month high of $273.57. The firm has a market capitalization of $8.55 billion, a P/E ratio of 1,115.28, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.63 million. During the same quarter last year, the firm earned $2.46 earnings per share. The business’s revenue for the quarter was down 1.1% on a year-over-year basis. On average, equities analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).